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Wehavepreviously shown that SV40 small t antigen (st) coop-
erates with deregulated cyclin E to activate CDK2 and bypass
quiescence in normal human fibroblasts (NHF). Here we show
that st expression in serum-starved and density-arrested NHF
specifically induces up-regulation and loading of CDC6 onto
chromatin. Coexpression of cyclin E results in further accumu-
lationofCDC6onto chromatin concomitantlywithphosphoryl-
ation ofCDK2onThr-160 andCDC6onSer-54. Investigation of
the mechanism leading to CDC6 accumulation and chromatin
loading indicates that st is a potent inducer of cdc6 mRNA
expression and increases CDC6 protein stability. We also show
that CDC6 expression in quiescent NHF efficiently promotes
cyclin E loading onto chromatin, but it is not sufficient to acti-
vate CDK2. Moreover, we show that CDC6 expression is linked
to phosphorylation of the activating T loop of CDK2 in serum-
starvedNHF stimulatedwithmitogens or ectopically expressing
cyclin E and st.Our data suggest amodelwhere the combination
of st and deregulated cyclin E result in cooperative and coordi-
nated activation of both an essential origin licensing factor,
CDC6, and anactivity required for origin firing,CDK2, resulting
in progression from quiescence to S phase.
Upon mitogenic stimulation mammalian G1 CDKs4 trigger
passage through the restriction point and the transition into
DNA replication. In particular, cyclin E/CDK2 is activated in
mid to late G1 and phosphorylates a variety of substrates that
play critical roles in these processes. CDK2 cooperates with
D-type cyclin/CDKs to inactivate E2F/pocket protein repressor
complexes inducing the expression of DNA synthesis factors
and other cell cycle regulators (reviewed inRefs. 1 and 2). CDK2
also phosphorylates DNA replication factors facilitating pre-
replication complex assembly and origin firing and plays addi-
tional roles in centrosome duplication and histone synthesis
(reviewed in Ref. 1). In particular, it has been proposed that
CDK2 phosphorylates the essential origin licensing factor
CDC6 promoting its stabilization prior to inactivation of the
APCCdh1 ubiquitin ligase (3). This is thought to ensure that
CDC6 accumulation precedes accumulation of other APC sub-
strates that inhibit origin licensing. Moreover, CDK2-inde-
pendent cyclin E functions have also been reported to be impor-
tant for prereplication complex assembly in cells in transit from
G0 intoG1 (4, 5). In keepingwith its role as positive regulator of
major G1 transitions, deregulation of the cyclin E via gene
amplification or defective protein turnover is commonly seen
in primary tumors and is associated with poor prognosis (6–8).
In normal fibroblasts, ectopic expression of cyclin E has been
associated with shortening of the G1 phase of the cell cycle (9,
10), and with induction of DNA damage (reviewed in Ref. 8).
Cyclin E deregulation in certain human tumor cell lines and
immortalized rat fibroblasts is associated with mitogen-inde-
pendent cell cycle entry and progression through the cell cycle
(11). However, when cyclin E is ectopically expressed in quies-
cent normal human fibroblasts (NHF), cells remain in G0 (12).
We have recently reported that coexpression of SV40 small t
antigen (st) in quiescent NHFwith deregulated cyclin E expres-
sion is sufficient to trigger mitogen-independent cell cycle pro-
gression, proliferation beyond cell confluence, and foci forma-
tion. The bypass of quiescence induced by the expression of st
and cyclin E is dependent on CDK2 activation (12). Thus, con-
trary to what is seen in normal murine cells (13), CDK2 activity
appears essential for cell cycle progression when it is oncogeni-
cally driven by cyclin E and st expression (12). Because st is
known to target pathways uniquely required for the transfor-
mation of human cells (14, 15), tumor cells with altered path-
ways that mimic st/cyclin E expression could predictably be
sensitive to selective inhibition of CDK2 activity.
Given the critical role of CDK2 activity in cyclin E and st
cooperation in inducing cell proliferation and transformation
ofNHF, we sought to determine the factors andmechanisms by
which st modulates CDK2 activation. In this report we have
identified the CDC6 replication licensing factor as a cellular
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target of st.We also uncoverCDC6as a participant in the events
leading to chromatin association of cyclin E and CDK2 and in
phosphorylation of CDK2 on its activating T loop both in
response to mitogenic stimulation, as well as expression of
cyclin E and st in NHF.
EXPERIMENTAL PROCEDURES
Cell Culture and Cell Cycle Synchronization—BJ-hTERT
immortalized fibroblasts were a gift from William C. Hahn
(Harvard Medical School, Dana-Farber Cancer Institute). All
cell lines were maintained in Dulbecco’s modified Eagle’s
medium (Cellgro) supplemented with 10% fetal bovine serum
(FBS) (Sigma) at 37 °C in a humidified atmosphere with 5%
CO2. Serum starvation was performed as previously described
(11). Density arrest was achieved by growing cells to high den-
sity until no dividing cells were visible under the microscope
and maintained for an additional 48 h prior to any treatment.
Progression of cells through the cell cycle was measured by
propidium iodide staining followed by flow cytometric analysis
(PI/FACS) using a BD FACSCalibur flow cytometer and quan-
tified with Cell Quest software (BD) as described earlier (11).
Recombinant Virus Production and Transduction—Recom-
binant adenoviruses encoding cyclin E were provided by Jeffrey
H. Albrecht (Hennepin CountyMedical Center). Adenoviruses
encoding p16 were provided by Juan Fueyo (The University of
Texas MD Anderson Cancer Center). Adenoviruses encoding
p21 were provided byWafik El-Deiry (University of Pennsylva-
nia). -Galactosidase adenoviruses were from Clontech.
Adenoviruses encoding EGFP were provided by Pilar Ruiz-
Lozano (Burnham Institute for Medical Research). Adenovi-
ruses encoding st were provided by Kathleen Rundell (North-
western University). Adenoviruses encoding CDC6 were
previously described (16). A mutant derivative of cdc6 (CDC6-
S3D) in which all three CDK target residues were converted to
aspartic acid was constructed by standard molecular biology
methods and packaged identically to normal Cdc6. Adenoviral
stocks were amplified using Ad-293 cells and purified by CsCl
density gradient centrifugation as described previously (11, 17).
Viral titers were determined with the Adeno-XTM Rapid Titer
Kit (BD Bioscience). NHF were transduced at a multiplicity of
infection (MOI) of 150 plaque-forming units/cell when syn-
chronized by serum starvation, or with an MOI of 40 when
synchronized by growth to high density. pBabe-puro-cyclin E
was obtained from Bruce Clurman (Fred Hutchinson Cancer
Research Center). pBabe-puro-Myc-CDC6 was generated by
cloning a BamHI/XhoI fragment encoding Myc-tagged CDC6
from pcDNA3-Myc5-CDC6 into the BamHI/XhoI site of
pBabe-puro. Retroviral vector expressing dominant negative
E2F1-pRB-A/B was kindly provided by Erik S. Knudsen (Kim-
mel Cancer Center, Thomas Jefferson University). 10 g of ret-
roviral plasmids were cotransfected with 5 g of pCL-Ampho
packaging vector (Imgenex), into 293T cells following the
calcium phosphate precipitation method (18). Retroviral
particles were harvested at 24- and 48-h post-transfection
and used to super-infect exponentially growing BJ-hTERT
cells. When indicated, clones were selected in the presence
of 1 g/ml puromycin.
Western Blot Analysis—Whole cell lysates were obtained in
buffer containing 50 mM Tris-HCl (pH 7.4), 5 mM EDTA, 250
mM NaCl, 50 mM NaF, 0.1% Triton X-100, 0.1 mM Na3VO4, 2
mM phenylmethylsulfonyl fluoride (PMSF), 10 g/ml leupep-
tin, 4 g/ml aprotinin, and 4 g/ml pepstatin as previously
described (11). Whole cell lysates were resolved by SDS-PAGE
and transferred to polyvinylidene difluoride (PVDF) mem-
branes for Western blot analysis as previously described (11).
The followingantibodieswereused forWesternblotanalysis: anti-
cyclin A (C19), anti-cyclin E (HE12), anti-CDK2 (M20), anti-
CDC6 (180.2), anti-CDC6 phospho-Ser54, anti-PP1 (FL18), and
anti-PCNA (PC10) antibodies were from Santa Cruz Biotechnol-
ogy, anti-MCM2 (BM28) antibody was from BD. Anti-pRB phos-
phospecific and anti-phospho-CDK2-T160 antibodies were from
Cell Signaling. Anti-st/LT 419 monoclonal antibodies were a gift
from ElizabethMoran (Temple University).
Preparation of Chromatin Fractions—Separation of chroma-
tin-bound from soluble proteins was performed as previously
described (5) using cytoskeletal (CSK) buffer: 10 mM PIPES-
KOH (pH 6.8), 100mMNaCl, 300mM sucrose, 3mMMgCl2, 0.5
mM PMSF, 0.1 mM glycerolphosphate, 50 mM NaF, 1 mM
Na3VO4, containing 0.1%Nonidet P-40 and protease inhibitors
2 mM PMSF, 10 g/ml leupeptin, 4 g/ml aprotinin, and 4
g/ml pepstatin. Briefly, cell pellets were lysed for 10min on ice
followed by 4000 rpm centrifugation for 5 min. The soluble
fraction was collected and cleared by high-speed centrifuga-
tion, 13,000 rpm for 5 min. Protein concentration was deter-
mined by Bradford assays. Pellets containing chromatin-bound
proteins were washed with CSK buffer and centrifuged at 4000
rpm for 5 min. Chromatin-bound proteins were solubilized in
1 Laemmli Sample Buffer and boiled for 5 min. Equal
amounts of chromatin and soluble fraction were loaded for
each sample.
RNA Extraction and Northern Blots Analysis—RNA was
extracted using RNeasy kit (Qiagen) and 5–10 g of RNA were
resolved in 1% agarose/0.6 M formaldehyde/1 MOPS gels.
RNA was transferred and UV-crosslinked onto Hybond-N.
Prehybridization and hybridization were performed at 45 °C in
UltraHyb solution (Ambion). 25 ng of denatured cDNA were
end-labeled at room temperature for 1 h with [-32P]ATP.
Radioactive signals were quantified using Image J software
(NIH) and normalized using ribosomal RNA bands. When
required, membranes were stripped by boiling in water for
5 min.
siRNA—Exponentially growing BJ-hTERT cells were plated
at 5,000 cells/cm density in 10-cm plates in complete DMEM.
Sixteen hours later, cells were serum-starved and transfected
with a mix of three different siRNA targeting CDC6 sequences
(1) 5-tctagccaatgtgcttgcaagtgta-3, (2) 5-caccatgctcagccatta-
aggtat-3, and (3) 5-aagaatctgcatgtgtgagac-3, (siRNAs target-
ing sequence 3 have been previously described in Ref. 19), or
control siRNA targeting EGFP or Renilla luciferase at a final
concentration of 75 nM siRNA using Dharmafect Reagent 4
(Dharmacon). A second siRNA transfection was performed
24 h later, and after 48 h cells were stimulated with FBS or
transduced with adenoviruses expressing cyclin E and st.
Cycloheximide (CHX) Assay—Density-arrested BJ-hTERT
cells expressing Myc-tagged CDC6 from a retroviral promoter
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were transduced with adenovirus expressing st or control
adenoviruses. Forty hours after transfection, cells were treated
with 10 M CHX, harvested at the indicated time points and
processed forWestern blot analysis as previously described (17,
20). Quantitation was done using Image J software (NIH) and
normalized by loading. To measure endogenous CDC6 stabil-
ity, BJ-hTERTcells were serum-starved for 48 h and transduced
with st or control adenoviruses and 16 h later stimulated with
FBS. TreatmentwithCHX started 20 h after serum stimulation.
RESULTS
We have previously shown that deregulation of cyclin E in
certain quiescent tumor/immortal cell lines leads to mitogen-
independent cell cycle entry and proliferation (11). In contrast,
expression of cyclin E in NHF at levels found in cancer cells is
not sufficient to induce mitogen-independent exit from quies-
cence (12). However, when cyclin E is deregulated in quiescent
NHF, co-expression of SV40 st induces mitogen-independent
cell cycle entry. Similarly, coexpression of st and cyclin E in
NHFbypasses quiescence induced by growth to high density. In
these scenarios, cyclin E/st driven cell cycle entry is character-
ized by a marked phosphorylation of CDK2 on its activating
T-loop and CDK2 activation. Importantly, CDK2 activation is
essential for these processes.
Our recentwork shows that st induces activation of a fraction
of cellular CDK2 complexes devoid from CKIs when coex-
pressed with cyclin E in quiescent NHF. However, we have not
observed overt disruption of cyclin E/CDK2/CKI complexes,
and cyclin E and st coexpression can induce cell cycle entry
when CKIs are expressed at very high levels (12). This suggests
that st creates a pool of cyclin E/CDK2 complexes that is pro-
tected fromCKI inhibition. Thus, we hypothesized that a factor
and/or a subcellular locationmaymediate this process. Because
cyclin E is recruited to replication complexes and cyclin E
and/or CDK2 play multiple roles in the modulation of these
complexes and the initiation of DNA replication (reviewed in
Ref. 1), we sought to determine if st modulates loading of cyclin
E/CDK2 complexes onto chromatin.
Expression of st in Quiescent Cells Induces Expression and
Loading of CDC6 ontoChromatin—hTERT immortalizedNHF
were serum-starved for 72 h and then stimulated with serum or
transduced with the indicated adenoviruses (Fig. 1A). The lev-
els of exogenous cyclin E expressed under these conditions are
comparable to the levels of cyclin E expressed in tumor cell lines
with deregulated cyclin E (12). Also, st expression is compara-
ble to that observed in NHF immortalized by SV40 (see supple-
mental Fig. S1). Cells were collected and lysed in CSK buffer to
separate soluble proteins from chromatin-bound proteins.
Strikingly, we found that st, but not cyclin E or control -galac-
tosidase, induces expression and loading onto chromatin of the
replication factor CDC6. CDC6, together with CDT1 associate
with origins of replication through interaction with origin rec-
ognition complex proteins (ORC) inG1 (reviewed inRef. 21). In
cooperation withORC andCDT1, CDC6 loads theMCMDNA
helicase complex at origins to prepare them for replication ini-
tiation during S phase.
CDC6 mRNA expression is negatively regulated via E2F-de-
pendent transcriptional repression, while the CDC6 protein is
actively targeted by the APCCdh1 ubiquitin-ligase for
proteasomal-dependent degradation in quiescent cells (22).
Thus, CDC6 expression and stabilization is thought to be
required for its loading onto chromatin and further recruit-
ment of other members of the replication machinery to repli-
cation origins. Recent work has implicated cyclin E/CDK2 in
CDC6 protein stabilization via phosphorylation of specific res-
idues that protect CDC6 from ubiquitination and subsequent
degradation (3). Consistent with this finding plus our previous
results that coexpression of cyclin E and st stimulates CDK2
activity (12), CDC6 expression and loading onto chromatin is
further up-regulated when both proteins are coexpressed (Fig.
1A). We also observed that ectopically expressed cyclin E
loaded onto chromatin in the absence of st, but st enhanced
cyclin E loading. It is important to note that st has not been
detected on the chromatin-bound fraction (Fig. 1A), nor was
phosphorylated pRB (data not shown), demonstrating the qual-
ity of our chromatin preparations. Similarly, in density arrested
BJ-hTERT fibroblasts, st but not cyclin E or control adenovirus
induced CDC6 expression and loading onto chromatin, and
CDC6 accumulation on chromatin correlated with increased
cyclin E loading (Fig. 1B). Moreover, the increase in CDC6 was
accompanied by enhanced loading of the MCM subunit,
MCM2, onto chromatin (Fig. 1B).
To determine if CDC6 expression and loading onto chroma-
tin facilitates cyclin E recruitment to chromatin, we expressed
cyclin E and wild-type CDC6 or a CDC6 mutant (CDC6-S3D)
resistant to degradation in density arrested BJ-hTERT fibro-
blasts. Resistance to degradation is due to substitution of three
primary CDK sites by Asp to mimic phosphorylation (3). This
mutant was selected, as exogenous wild type CDC6 is very
FIGURE 1. st induces expression and loading of CDC6 onto chromatin in
quiescent NHF, and CDC6 facilitates loading of cyclin E. BJ-hTERT fibro-
blasts were serum-starved for 72 h (A) or grown to high density as described
under “Experimental Procedures” (B and C) and then transduced with the
indicated adenoviruses or re-stimulated with FBS. Forty-eight hours follow-
ing transduction, cells were harvested, and chromatin-bound and soluble
fractions were obtained as described under “Experimental Procedures.”
15 g of the soluble protein fractions and the corresponding equivalent
chromatin-bound fractions were analyzed by Western blot using the indi-
cated antibodies. Same exposure times are shown for both fractions. Coo-
massie Blue staining of the gel is shown as a loading control. Relevant
proteins are indicated. Note that as reported earlier exogenously
expressed cyclin E migrates as a series of bands that migrate faster that
endogenous cyclin E (12).
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unstable in quiescent cells, even when its expression is con-
trolled by a CMV promoter (Fig. 1C). As expected, expression
of CDC6-S3D was efficient resulting in its own loading onto
chromatin and clearly enhanced cyclin E loading, as compared
with cyclin E alone or cyclin E coexpressedwithwild typeCDC6
(Fig. 1C). This mutant did not sub-
stitute for st, as serum-starved
fibroblasts co-expressing CDC6-
S3D and cyclin E did not exit quies-
cence (data not shown). This could
indicate that st has other targets in
addition to CDC6 potentially im-
portant for CDK2 activation. For
instance, we have previously shown
st increases CAK activity in serum-
starved NHF (12).
A time course experiment was
performed to correlate the effects of
st on CDC6 with the chromatin
loading of CDK2 and other replica-
tion factors. Fig. 2A shows that st,
but not -galactosidase, induced
CDC6 loading, even at the earliest
time point analyzed. Co-expression
of cyclin E and st resulted in time-
dependent increase in the amount
of CDC6 over that observed with st
alone, and this increase correlates
with CDK2 accumulation and phos-
phorylation on Thr-160, and subse-
quent PCNA loading (Fig. 2A). Of
note, we did not observe recruit-
ment of CKIs with CDK2 onto chromatin (data not shown).
FBS induced earlier and higher accumulation and loading of
CDC6, which correlates with Thr-160 phosphorylation and
PCNA loading (Fig. 2A). As CDK2 has been implicated in phos-
phorylation and stabilization of CDC6, we determined the
effects of stimulating serum-starvedNHFwith FBS on Thr-160
phosphorylation and the phosphorylation of CDK2 substrates
on both the soluble and chromatin-bound fraction. Interest-
ingly, we found that CDK2Thr-160 phosphorylation correlates
with pRB phosphorylation (Thr-826) in soluble fraction and
withCDC6phosphorylation on Ser-54 in the chromatin-bound
fraction (Fig. 2B). Thus, st expression suffices to induce
expression and chromatin loading of CDC6, a component of
the prereplication complex, with little effect on CDK2 Thr-
160 phosphorylation, and coexpression of cyclin E triggers
additional CDC6 accumulation along with coordinated Thr-
160 phosphorylation.
st Induces Modest Stabilization of CDC6—We next deter-
mined the effects of st on CDC6 protein stability using protein
half-life CHX assays. Because the levels of CDC6 in quiescent
cells are extremely low and CDC6 becomes undetectable
shortly after addition of CHX, we generated BJ-hTERT fibro-
blasts stably expressing wild type Myc-tagged CDC6 via retro-
viral transduction and short puromycin selection. Exogenous
Myc-CDC6 levelswere comparable to endogenousCDC6 levels
in the presence of serum (data not shown). Serum-starved BJ-
hTERT-CDC6 cells were transduced with st or -galactosidase
adenoviruses for 24 h and then treated with CHX for the indi-
cated times (Fig. 3). Expression of st in serum-starved
BJ-hTERT-CDC6 fibroblasts increased the stability of CDC6 by
65% (from 20 to 33 min, Fig. 3). This experiment was also per-
FIGURE 2. st expression in serum-starved NHF induces CDC6 expression and loading, which is enhanced
by coexpression of cyclin E. The kinetics of phosphorylation of CDK2 on Thr-160 and CDK2 substrates is
distinct in the soluble and chromatin-bound fraction. BJ-hTERT fibroblasts were serum-starved for 72 h and
transduced with indicated adenoviruses (A) or re-stimulated with serum (A and B) and harvested at indicated
time points. Soluble and chromatin-bound proteins were obtained and simultaneously analyzed by Western
blot. Same exposure times are shown for both fractions. Coomassie Blue staining is shown as a loading control.
Relevant proteins are indicated. The CDK2 band corresponding to phosphorylated Thr-160 is indicated with an
asterisk.
FIGURE 3. st increases CDC6 protein stability. Density-arrested BJ-hTERT
fibroblasts stably expressing Myc-tagged CDC6 from a retroviral plasmid
were transduced with adenovirus expressing st or control -galactosidase.
Forty hours after transduction, cells were treated with 10 M CHX and har-
vested at the indicated time points. Whole cell lysates were analyzed by West-
ern blot. CDC6 signal was quantified relative to time 0 and normalized to the
PP1 signal, which is stable through the time course.
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formed using CDC6 transiently expressed from an adenoviral
vector with similar results (data not shown).
cdc6 mRNA Expression Is Potently Up-regulated by st in Qui-
escent BJ-hTERT Cells to Levels Similar to Those Induced by
Mitogens—As mentioned above, CDC6 expression is not only
regulated via proteasomal-dependent degradation, but also by
transcriptional, E2F-dependent, and independentmechanisms.
Therefore, we determined whether cdc6 and other inducible
mRNAs are regulated by st expression in density arrested NHF
as compared with proliferating cells. Interestingly, we found
that st expression increased cdc6 mRNA to levels comparable
to those seen in exponentially growing cells (Fig. 4A). In con-
trast, themRNAs corresponding to other E2F-dependent genes
and c-Myc, were only slightly up-regulated by st expression but
were robustly expressed in exponentially growing cells (Fig. 4A,
right panel). Next we determined the kinetics of expression of
these mRNAs in response to serum stimulation (Fig. 4B) or st
expression in density-arrested (Fig. 4C) or serum-starved (Fig.
4D) BJ-hTERT fibroblasts. In these cells, cdc6 mRNA reaches
its maximum 14 h after serum stimulation, closely followed by
other E2F targets, such as cdk2 and cyclin A, and then is quickly
down-regulated, as cells progress through S and G2/M (Fig.
4B). Strikingly, transduction with st adenovirus induced robust
cdc6 mRNA accumulation within a relatively short period of
time after transduction in both density-arrested (Fig. 4C) and
serum-starved cells (Fig. 4D). Moreover, these experiments
clearly show that st expression preferentiallymodulates cdc6 as
comparedwith three other E2F targets, cyclinA, cdk2, and e2f1.
In particular, st induces cdc6 expression 14- and 29-fold in
serum-starved and density-arrested NHF, respectively, while
the other mRNAs analyzed increased only by 2–4-fold. This
2–4-fold increase may be due to a modest general effect on
gene expression, as we have seen similar effects on the expres-
sion of viral promoters (data not shown). Because st induces
both cdc6 mRNA and protein accumulation, we wanted to
determine if both events occur simultaneously, or if one clearly
preceded the other. Hence, density-arrested BJ-hTERT cells
were transducedwith st adenoviruses and collected at indicated
time points (supplemental Fig. S2). Each cell pellet was divided
in two for RNA and protein extractions. Northern andWestern
FIGURE 4. cdc6 mRNA expression is potently up-regulated by st in serum-starved and density-arrested BJ-hTERT cells. A, BJ-hTERT cells were
grown to high density and transduced with 40 MOI of adenovirus expressing st and/or control EGFP and harvested 30 h later. Exponentially growing
cells were used as controls. Levels of expression of indicated mRNAs were analyzed by Northern blot as described under “Experimental Procedures.”
Radioactive signals were measured by densitometry, quantified with NIH Image J, and represented as fold increase. B, BJ-hTERT fibroblasts were
synchronized by serum starvation for 72 h, re-stimulated with 10% FBS and harvested at indicated time points for Northern blot analysis as in A.
C, BJ-hTERT cells were grown to high density, transduced with adenovirus expressing st and harvested at indicated time points after transduction and
treated as in A. D, BJ-hTERT cells were serum-starved for 72 h, transduced with adenovirus expressing st and harvested at indicated time points after
transduction and treated as in A.
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blot analyses revealed that the kinetics or up-regulation at
mRNAandprotein levels are similar at the time points analyzed
suggesting that these processes are coordinated (supplemental
Fig. S2).
st Induces cdc6 mRNA Expression in an E2F-dependent, but
CDK-independent Manner—cdc6 expression is controlled at
the transcriptional level via E2F-dependent and independent
mechanisms (23–26). As cells enterG1, cdc6mRNAexpression
is thought to result frommitogenic activation of G1 CDKs that
in turn phosphorylate pocket proteins disrupting E2F/pocket
protein repressor complexes located at E2F promoter elements.
However, st-mediated up-regulation of cdc6 mRNA occurs in
the absence of CDK2 activity or pocket protein phosphoryla-
tion (12). Therefore, we sought to determine whether st medi-
ated up-regulation of cdc6mRNAwas dependent or independ-
ent of E2F and CDK activity. BJ-hTERT cells were transduced
with a retroviral vector expressing a dominant negative version
of E2F1 (E2F1A/B) consisting of the E2F DNA-binding and
dimerization domains fused to the A/B pocket of RB (27), or
with retrovirus control (r-control). After antibiotic selection,
cells were serum-starved for 72 h and subsequently re-stimu-
lated with serum or transducedwith st or control adenoviruses.
Northern blot analyses confirmed that cdc6 mRNA expression
induced by FBS was greatly inhibited (4-fold) in the presence
of the dominant-negative E2F (Fig. 5,A and B). Upon st expres-
sion, dominant negative E2F also caused prominent inhibition
of cdc6 mRNA expression (3-fold) (Fig. 5, A and B), indicating
that transcription of cdc6 induced by st in quiescent cells
depends, at least partially, on E2F.
To assess the importance of CDK activity on st-induced cdc6
mRNA, BJ-hTERT cells were serum-starved for 48 h and trans-
duced with p16 and p21 adenovi-
ruses for 24 h. Subsequently, cells
were stimulated with serum or
transduced with st or control
adenoviruses. Northern blot ana-
lysis confirmed that serum-
dependent expression of cdc6
requires CDK activity (Fig. 5, C and
D). In contrast, st-mediated induc-
tion of cdc6mRNAwas not affected
by overexpression of CKIs. Consid-
ering that co-overexpression of p21
and p16 potently blocks the kinase
activity of all cell cycle CDKs, it
appears that st-mediated up-regula-
tion of cdc6 mRNA is independent
of CDK-mediated phosphorylation
of pocket proteins despite being
dependent on E2F promoter ele-
ments. This striking result suggests
that st regulates CDC6 mRNA
expression by mechanisms up-
stream of pocket proteins that do
not require pocket protein inactiva-
tion via canonical CDK inactivation
pathways. These andother potential
alternative mechanisms are consid-
ered in the discussion.
CDC6 Expression and Loading onto Chromatin Are Coupled
to Phosphorylation of CDK2 on Thr-160 during Mitogen-de-
pendent Cell Cycle Entry—Taking into account the close corre-
lation that we have observed betweenCDC6 expressionwith its
loading onto chromatin and the phosphorylation of CDK2 on
Thr-160 (Fig. 2, A and B), we next determined the effect that
CDC6 depletion in cells has on CDK2 phosphorylation under
physiological conditions. BJ-hTERT cells were transfected with
chemically synthesized siRNA directed to CDC6 (a mixture of
two distinct siRNAs 1 and 2) or Renilla firefly (control) and
subsequently serum-starved for 48 additional hours in Dulbec-
co’s modified Eagle’s medium. Next, cells were stimulated with
FBS or left untreated. Fig. 6A shows that the CDC6 but not the
Renilla siRNA effectively knocked-down CDC6. Most impor-
tantly, preventing CDC6 expression reduces phosphorylation
ofCDK2onThr-160 dramatically, both in the soluble and chro-
matin-bound fraction (Fig. 6A), suggesting a close link between
CDC6 expression andCDK2 activation. This decrease in CDK2
Thr-160 phosphorylation was accompanied by a noticeable but
much less prominent decrease on pRB phosphorylation and
cyclinA expression. Near normal pRB inactivation and E2F-de-
pendent gene expression is consistent with the effects of the
double cyclin E1;E2 knock-out in mice, where these events are
only slightly reduced, as D-type cyclin/CDK complexes are suf-
ficient to inactivate pocket proteins and induce E2F gene
expression (4). To confirm that knockdown of the essential fac-
tor CDC6 prevents cell cycle entry and progression through S
phase a time course experiment was performed. Exponentially
growing BJ-hTERT cells were transfected with a mixture of
three siRNAs targeting CDC6 in serum-free medium. Cells
FIGURE 5. st induces CDC6 mRNA expression in a CDK-independent, E2F-dependent manner. A, BJ-hTERT
cells stably expressing a dominant negative E2F/pRB mutant chimera or the empty expression vector (r-con-
trol) (see text) were serum-starved for 72 h immediately after antibiotic selection and re-stimulated with FBS or
transduced with control or st adenovirus. Cells were harvested for RNA analysis 40 h later. B, radioactive signals
were quantified, normalized by ribosomal RNA loading, and represented as fold increase in mRNA as in Fig. 4.
C, BJ-hTERT cells were serum-starved for 48 h and transduced with adenovirus expressing p21 and/or p16.
Twenty-four hours later, cells were re-stimulated with FBS or transduced with st adenovirus. Forty hours later,
cells were harvested for Northern blot analysis. D, radioactive signal was quantified as in B.
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were re-transfected with the same siRNAs 24 h later and main-
tainedwithout serum for additional 48 h prior to re-stimulation
with FBS. Cells were collected at indicated time points, and the
pellets were divided in two for PI/FACS analysis and prepara-
tion of soluble and chromatin-bound proteins. Fig. 6B shows
that the CDC6, but not EGFP, siRNAs effectively knocked-
down CDC6. As in Fig. 6A, preventing CDC6 expression
reduced phosphorylation of CDK2-Thr-160 in both the soluble
and chromatin fractions (Fig. 6B). Inhibition of CDC6 expres-
sion also inhibited loading of MCM2 onto chromatin (Fig. 6B),
as well as cell cycle entry induced by serum (Fig. 6C). Thus,
CDC6 expression appears important for effective phosphoryl-
ation and activation of CDK2.
CDC6 Expression and Loading onto Chromatin Are Coupled
to Phosphorylation of CDK2 on Thr-160 and Cell Cycle Entry
Induced by Deregulated Cyclin E and st Co-expression—We
next analyzed if CDC6 was also necessary for CDK2 phospho-
rylation and cell cycle entry of quiescent fibroblasts expressing
deregulated cyclin E and st. BJ-hTERT cells were transfected
with siRNA targeting CDC6 as described above. Forty-eight
hours after the second round of transfection, cells were trans-
duced with adenoviruses expressing cyclin E and st. As shown
in Fig. 7A, knock-down of CDC6 inhibits CDK2 phosphoryla-
tion in both the soluble and chromatin fractions. The most
striking effect of CDC6 knockdown on cyclin E/CDK2 was
observed in the chromatin fractions. Reducing CDC6 by siRNA
not only reduced the normal G1 loading of MCM2 onto chro-
matin as expected, but also greatly impaired the amount of both
cyclin E and CDK2 in the chromatin fractions, suggesting that
Cdc6 is required for robust association of cyclin E/CDK2 with
chromatin. Concomitantly, cells transfected with CDC6 siRNA
showed a clear delay in cell cycle entry (Fig. 7B). This result
indicates that CDC6 is critical for the cooperative effects that
deregulated cyclin E and st have on NHF, including the phos-
phorylation and chromatin association of cyclin E/CDK2 and
entry in to S phase from quiescence.
FIGURE 6. CDC6 expression is coupled to phosphorylation of CDK2 on Thr-160 and exit from quiescence induced by serum. A, BJ-hTERT cells
were transfected with siRNAs targeting CDC6 or renilla luciferase in conditions of serum starvation. Forty-eight hours later, cells were restimulated with
10% FBS, and 48 h after restimulation, cells were harvested and lysed for soluble/chromatin-bound protein fractionation and Western blot analysis.
B and C, BJ-hTERT cells were transfected with siRNAs targeting CDC6 or EGFP in conditions of serum starvation. Seventy-two hours later, cells were
re-stimulated with FBS and harvested at the indicated time points. Cell pellets were divided in two for soluble/chromatin-bound protein fractionation
and Western blot analysis (B) and PI/FACS analysis (C). A and B, same exposure times are shown for both fractions. B, CDK2 band corresponding to
phosphorylated Thr-160 is indicated with an asterisk. LE indicates long exposure. SE indicates short exposure. C, percent of cells in each cell cycle phase
is indicated.
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DISCUSSION
Cyclin E deregulation is frequently observed in breast carci-
nomas, leukemias and lymphomas, cervical carcinomas, gastro-
intestinal cancers, as well as early bladder lesions and colon
adenomas among others and is often linked to poor prognosis
(Refs. 6 and 7, reviewed in Ref. 8). We have previously shown
that deregulated cyclin E expression cooperates with SV40 st to
induce exit from quiescence in the absence of mitogens, as well
as continuous proliferation of density-arrested NHF and foci
formation. In this oncogenic context, CDK2 activation is
required for cell cycle progression (12). Here we have identified
the replication licensing factor CDC6 as a cellular target
strongly and specifically induced by st expression.When cyclin
E is concomitantly deregulated, subsequent accumulation of
CDC6protein stimulates origin licensing and is linked toCDK2
phosphorylation on its activating T loop leading to CDK2 acti-
vation and driving quiescent cells into S phase.
st Induces Unscheduled CDC6 Expression, Stabilization, and
Loading onto Chromatin—CDC6 is an essential component of
the pre-replication complex that is not expressed in quiescent
mammalian cells and is tightly regulated throughout the cell
cycle to prevent unscheduled or multiple firing of replication
origins. Efficient firing of an origin of replication requires the
binding of CDT1 and CDC6 to the origin of replication com-
plex (ORC), as well as subsequent loading of theMCMhelicase
(reviewed in Refs. 21, 28–30). It has been shown that loading of
theMCMhelicase requires cyclin E protein (but not necessarily
CDK2 kinase activity) as cells are stimulated to enter G1 from
quiescence (5). Also, cyclin E/CDK2 complexes phosphorylate
and stabilize CDC6 in G1 by preventing its ubiquitination by
the APCCdh1 ligase, ensuring accumulation of CDC6 and for-
mation of prereplication complexes (3). Here we report that
expression of st in quiescent NHF induces accumulation of
both cdc6 mRNA and protein, as well as loading onto chroma-
tin, but st-mediated CDC6 accumulation is not sufficient to
induce mitogen independent DNA
synthesis in untransformed cells.
However, when cyclin E is co-ex-
pressed with st in quiescent cells,
CDC6 expression, and loading onto
chromatin are significantly in-
creased and this coincides with
phosphorylation of CDK2 on Thr-
160 and DNA synthesis.
Investigation of the mechanisms
leading to increased cdc6 mRNA
expression by st showed sensiti-
vity to E2F-mediated repression.
Because we have not observed
st-mediated stabilization of cdc6
mRNA species (data not shown),
our data suggest E2F-dependent
transcriptional regulation. The sen-
sitivity to E2F could indicate a
mechanism of regulation similar to
that induced by mitogens in quies-
cent cells, which is mediated via
derepression of E2F-pocket protein
complexes and subsequent transactivation by activating E2Fs
(31). However, our data show that st alone induces cdc6mRNA
in quiescent NHF overexpressing CKIs, which presumably
inactivate any potential trace of G1/S CDK activity. In this
regard, we have not detected CDK2 activity in st expressing
NHF (12). It has been suggested that st-mediated regulation of
the cyclin A promotermay be dependent on inactivation of p27
(32). In contrast, cdc6 mRNA induction by st expression is just
as efficient in the presence of ectopically expressed CKIs as it is
in their absence. Thus, st-dependent up-regulation of cdc6
expression does not occur strictly via canonical downstream
stimulation of mitogenic pathways that activate CDKs.
Instead, st may modulate E2F repressor complexes by a dis-
tinct and novel mechanism. One possibility is that since E2F/
pocket protein complexes recruit histone deacetylases
(HDAC), chromatin remodeling complexes (SWI/SNF), and
histone methyltransferases at E2F elements (31), st expression
may modulate these complexes independently of CDK-medi-
ated phosphorylation. An alternative option may be that st
affects the activity of YY1 or YY1 interaction with E2F, since
that E2F cofactor is more specific for cdc6 than for other E2F
targets (33). Yet another possibility is based on a recent study
showing that IBkinase activation inhibits cell growth andE2F-
dependent transcription in NHF in a pocket protein-indepen-
dent manner. NF-B/p65 disrupts the physical interaction
between activator E2Fs and the HAT cofactor TRRAP, result-
ing in reduction in E2F-responsive gene expression (34). Fur-
thermore, previous studies have shown that st induces cyclin A
mRNAexpression in quiescentmonkeyCV-1 cells and foreskin
human diploid fibroblasts (35). Although we have also detected
verymodest up-regulation of other E2F-regulated genes such as
cyclin A in st-expressing density-arrested BJ-TERT cells,
induction of cdc6mRNA expression by st is muchmore potent
and comparable in magnitude to that induced via mitogenic
stimulation. Moreover, the induction of cdc6 mRNA results in
FIGURE 7. CDC6 expression is required for phosphorylation of CDK2 on Thr-160 and exit from quiescence
induced by deregulated cyclin E and st co-expression. BJ-hTERT cells were transfected with the indicated
siRNA and serum-starved as in Fig. 6. Subsequently the cells were transduced with adenovirus expressing
cyclin E and st and harvested 34 h later. Cell pellets were divided in two for soluble/chromatin-bound protein
fractionation and Western blot analysis (A) and PI/FACS analysis (B). A, same exposure times are shown for both
fractions. Relevant proteins are indicated. The CDK2 band corresponding to phosphorylated Thr-160 is indi-
cated with an asterisk. LE indicates long exposure. SE indicates short exposure. B, percent of cells in each cell
cycle phase is indicated.
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a significant increase in CDC6 protein and its loading onto
chromatin, but cyclin A protein and the products of other E2F-
dependent genes are not substantially up-regulated. Thus, it
appears that cdc6 is a particularly specific target of st. Clearly,
the regulation of cdc6 mRNA accumulation is more complex
than simple CDK-mediated pocket protein inactivation, and
our findings demonstrate that the effects of st on cdc6 mRNA
accumulation cannot be fully explained by global changes in
E2F-dependent gene expression.
In addition to increased cdc6 mRNA expression, we have
found that the CDC6 protein is induced by st in serum-
starved and density-arrested cells as result of increased half-
life. The reported CDC6 half-life is about 15–30 in G1 and
increases to 2 h in S phase (22, 36). The increase in protein
stability induced by st is modest in the absence of serum
(from 20 to 33), but appears consistent with the magnitude
of increase in protein expression. Also, the increase in CDC6
expression correlates with its phosphorylation on a CDK
site, which has been previously shown to stabilize CDC6 in
G1 (3). st may promote CDC6 phosphorylation by targeting
PP2A holoenzymes containing the PR70 B subunit, which
has been recently implicated in stabilization of CDC6 by
dephosphorylation of CDK sites (37). The implication of
PR70 and other B subunits in this process will require further
studies.
CDC6 May Play a Role as an Upstream Regulator of CDK2—
Our data show that phosphorylation of CDK2 on its activat-
ing T loop and, hence, its activation is coupled to CDC6 expres-
sion in both serum-starved NHF coexpressing cyclin E and st
and mitogen-stimulated NHF. We have previously shown that
expression of st in quiescent NHF with deregulated cyclin E
does not result in activation of CDK2 by inducing the abrupt
dissociation of CKIs from CDK2 (12). In this report, we have
shown that CDC6 knockdown diminishes CDK2 loading onto
chromatin and conversely ectopic expression of CDC6
increases cyclin E loading onto chromatin. Therefore, as has
been suggested by earlier studies in vitro (38), CDC6may play a
role in recruitment of CDK2 complexes to origins of replica-
tion. The mechanism of this recruitment could be by compet-
ing with CKIs for binding to the cyclin E/CDK2 complex (Fig.
8). Supporting this possibility, it has recently been shown that
during recovery from a chemical DNAdamage checkpoint, p21
dissociation from CDK2 complexes is accelerated by overex-
pression of CDC6, which binds CDK2 coinciding with p21 dis-
sociation (39). More importantly, CDC6 activates p21-bound
CDK2 in an ATP-dependent manner in vitro and mutation of
CDC6 cyclin binding or ATPase domains precludes recovery
from the checkpoint arrest in cells (39). Thus, considering that
CDC6 candisplace p21 in vitro, it is conceivable thatCDC6may
compete with CKIs for binding to CDK2, thereby recruiting
CDK2 complexes to origins of replication to phosphorylate
specific substrates. Moreover, it has been previously proposed
based on structural data that CKI binding to CDK2 interferes
with the docking of CAK (40, 41). Thus, the absence of CKI
corecruitment with CDK2 onto chromatin, the correlation of
CDC6 expression and Thr-160 phosphorylation, and the
dependence of this phosphorylation event onCDC6 expression
may indicate that recruitment of CKI-free cyclin E/CDK2 com-
plexes by CDC6 to chromatin facilitates CAK access to the T
loop (Fig. 8). Conversely, the ability of monomeric CDK2 to
autophosphorylate on Thr-160 has been recently proposed
(42).Hence, stmay alternatively stimulateCDK2 autophospho-
rylation in a manner that is dependent on deregulated cyclin E
expression and independent from CAK. This st activity could
precede a subsequent CDC6 role in displacingCKIs from cyclin
E/CDK2 complexes prephosphorylated on Thr-160 leading to
CDK2 activation. This scenario is compatible with our previous
finding that the fractions of CKI/cyclin E/CDK2 and cyclin
E/CDK2 complexes are phosphorylated on Thr-160 at similar
levels (12). Further studies are needed to distinguish among
these possibilities.
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FIGURE 8. Model of events linking CDC6 and CDK2 activation during exit
from quiescence induced by cyclin E and st coexpression or mitogens.
A, expression of st and deregulated cyclin E expression in quiescent NHF
result in cooperative activation of the essential origin licensing factor CDC6
and coordinated CDK2 activation. st potently induces CDC6 mRNA expres-
sion and to a lower extent CDC6 phosphorylation on a CDK site(s) and stabi-
lization. st also facilitates loading of CKI free cyclin E/CDK2 onto chromatin,
which correlates with CDK2 phosphorylation on the activating T loop. CDC6
may facilitate CAK access to the CDK2 T loop, which could be prevented by
CKIs. Alternatively st may induce CDK2 autophosphorylation on Thr-160
(arrow with question mark; see text). Coexpression of cyclin E and st also
enhances CDC6 phosphorylation and loading onto chromatin suggesting
positive feedback loops leading to activation of CDK2 and CDC6 accumula-
tion (indicated by reciprocal arrows). B, mitogens may use similar mechanisms
to activate CDK2 on chromatin.
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11. Calbó, J., Parreño,M., Sotillo, E., Yong, T.,Mazo,A., Garriga, J., andGraña,
X. (2002) J. Biol. Chem. 277, 50263–50274
12. Sotillo, E., Garriga, J., Kurimchak, A., and Graña, X. (2008) J. Biol. Chem.
283, 11280–11292
13. Ortega, S., Prieto, I., Odajima, J., Martin, A., Dubus, P., Sotillo, R., Barbero,
J. L., Malumbres, M., and Barbacid, M. (2003) Nat. Genet. 35, 25–31
14. Hahn, W. C., Dessain, S. K., Brooks, M. W., King, J. E., Elenbaas, B., Saba-
tini, D. M., DeCaprio, J. A., andWeinberg, R. A. (2002)Mol. Cell. Biol. 22,
2111–2123
15. Deeb, K. K., Michalowska, A. M., Yoon, C. Y., Krummey, S. M., Hoener-
hoff, M. J., Kavanaugh, C., Li, M. C., Demayo, F. J., Linnoila, I., Deng, C. X.,
Lee, E. Y., Medina, D., Shih, J. H., and Green, J. E. (2007) Cancer Res. 67,
8065–8080
16. Cook, J. G., Park, C. H., Burke, T. W., Leone, G., DeGregori, J., Engel, A.,
and Nevins, J. R. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 1347–1352
17. Garriga, J., Bhattacharya, S., Calbo, J., Marshall, R. M., Truongcao, M.,
Haines, D. S., and Graña, X. (2003)Mol. Cell. Biol. 23, 5165–5173
18. Ausubel, F. M., Brent, R., Kington, R. E., Moore, D. D., Seidman, J. G.,
Smith, J. A., and Struhl, K. E. (1988) Current Protocols in Molecular Biol-
ogy, Greene Publishing Associates and Wiley-Interscience, NY
19. Melixetian, M., Ballabeni, A., Masiero, L., Gasparini, P., Zamponi, R., Bar-
tek, J., Lukas, J., and Helin, K. (2004) J. Cell Biol. 165, 473–482
20. Bhattacharya, S., Garriga, J., Calbo, J., Yong, T., Haines, D. S., and Graña,
X. (2003) Oncogene 22, 2443–2451
21. Diffley, J. F. (2004) Curr. Biol. 14, R778–786
22. Petersen, B. O., Wagener, C., Marinoni, F., Kramer, E. R., Melixetian, M.,
Lazzerini Denchi, E., Gieffers, C.,Matteucci, C., Peters, J.M., andHelin, K.
(2000) Genes Dev. 14, 2330–2343
23. Hateboer, G., Wobst, A., Petersen, B. O., Le Cam, L., Vigo, E., Sardet, C.,
and Helin, K. (1998)Mol. Cell. Biol. 18, 6679–6697
24. Ohtani, K., Tsujimoto, A., Ikeda, M., and Nakamura, M. (1998) Oncogene
17, 1777–1785
25. Vilaboa, N., Bermejo, R., Martinez, P., Bornstein, R., and Cales, C. (2004)
Nucleic Acids Res. 32, 6454–6467
26. Yan, Z., DeGregori, J., Shohet, R., Leone, G., Stillman, B., Nevins, J. R., and
Williams, R. S. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 3603–3608
27. Sellers,W. R., Rodgers, J.W., andKaelin,W.G., Jr. (1995)Proc. Natl. Acad.
Sci. U. S. A. 92, 11544–11548
28. Machida, Y. J., Hamlin, J. L., and Dutta, A. (2005) Cell 123, 13–24
29. Machida, Y. J., and Dutta, A. (2005) J. Biol. Chem. 280, 6253–6256
30. Sclafani, R. A., and Holzen, T. M. (2007) Annu. Rev. Genet. 41, 237–280
31. Rowland, B. D., and Bernards, R. (2006) Cell 127, 871–874
32. Skoczylas, C., Henglein, B., and Rundell, K. (2005) Virology 332, 596–601
33. Schlisio, S., Halperin, T., Vidal, M., and Nevins, J. R. (2002) EMBO J. 21,
5775–5786
34. Araki, K., Kawauchi, K., and Tanaka, N. (2008) Oncogene 27, 5696–5705
35. Porras, A., Bennett, J., Howe, A., Tokos, K., Bouck, N., Henglein, B.,
Sathyamangalam, S., Thimmapaya, B., and Rundell, K. (1996) J. Virol. 70,
6902–6908
36. Duursma, A. M., and Agami, R. (2005) Cell Cycle 4, 1725–1728
37. Davis, A. J., Yan, Z., Martinez, B., andMumby, M. C. (2008) J. Biol. Chem.
283, 16104–16114
38. Furstenthal, L., Kaiser, B. K., Swanson, C., and Jackson, P. K. (2001) J. Cell
Biol. 152, 1267–1278
39. Kan, Q., Jinno, S., Yamamoto, H., Kobayashi, K., and Okayama, H. (2008)
Proc. Natl. Acad. Sci. U. S. A. 105, 4757–4762
40. Lolli, G., and Johnson, L. N. (2005) Cell Cycle 4, 572–577
41. Lolli, G., Lowe, E. D., Brown, N. R., and Johnson, L. N. (2004) Structure 12,
2067–2079
42. Abbas, T., Jha, S., Sherman, N. E., and Dutta, A. (2007) Cell Cycle 6,
843–852
Cooperative Activation of CDC6 and CDK2 by st and Deregulated Cyclin E
MAY 22, 2009 • VOLUME 284 • NUMBER 21 JOURNAL OF BIOLOGICAL CHEMISTRY 14135
